In Novo Nordisk's largest market, the USA, sales of Wegovy have grown by 44 percent in the first quarter. (Archive photo). Photo: Hollie Adams/Reuters
Novo Nordisk’s obesity drug sales nearly doubled
Novo Nordisk nearly doubled the sales of its obesity drug Wegovy in the first quarter of 2025, reaching 17.4 billion DKK compared to 9.4 billion DKK the previous year. The US remains its primary market, with Wegovy sales increasing by 44%. Their total revenue grew by 19% to 78.1 billion DKK, and...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?